WuXi, PRA enter JV agreement to provide clinical trial services in China
WuXi PharmaTech and PRA have entered into a joint venture (JV) agreement to provide Phase I-IV clinical trial services in China including Hong Kong and Macau.
Under the agreement, WuXi will provide JV with clinical and regulatory services from its China-based clinical organization as well as supply laboratory services through a preferred provider arrangement.
PRA will offer clinical research services as well as support the JV with its China-based staff and global technology capabilities, encompassing data capture, trial management and other IT systems.
WuXi PharmaTech chairman and CEO Ge Li said, "Biopharmaceutical companies increasingly need sophisticated clinical-trial management services to gather the highest-quality data in Chinese patients to complete Chinese and international regulatory filings as quickly and successfully as possible."
PRA president and CEO Colin Shannon said the company's global experience and technical expertise combined with WuXi's operational experience and knowledge in China are a perfect fit.
"Clinical trials continue to expand in China, and this joint venture is another step we are taking to meet the needs of our clients by establishing a strong presence there," Shannon added.
"We look forward to working with WuXi to serve global life science companies conducting studies in China."